Introduction

MCO

Molecular and Clinical Oncology

2049-9450 2049-9469

D.A. Spandidos

MCO-25-4-02974

10.3892/mco.2026.2974

Articles

Clinicopathological features and prognoses of HER-2-positive gastric cancer

Shen

Huiqun

1 Xue

Xiajuan

2 He

Huiduan

3 Lin

Shujun

1Department of Oncology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian 363000, P.R. China 2Department of Colorectal Surgery, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian 363000, P.R. China 3Department of Pathology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian 363000, P.R. China

Correspondence to: Dr Shujun Lin, Department of Oncology, Zhangzhou Affiliated Hospital of Fujian Medical University, 59 Sheng Li Road West, Xiangcheng, Zhangzhou, Fujian 363000, P.R. China linsj932@163.com

102026

03092026

25 4

12 11 2025 19 08 2026

2026

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The present study aimed to investigate the clinicopathological characteristics of human epidermal growth factor receptor-2 (HER-2)-positive gastric cancer and their association with HER-2 protein expression levels and prognosis. In total, 99 patients diagnosed with HER-2-positive gastric cancer who underwent radical gastrectomy were included in the study. χ² testing explored the association between HER-2 protein expression and clinical features. Disease-free survival (DFS) and overall survival (OS) were evaluated through Kaplan-Meier survival curves. Univariate and multivariate Cox regression analyses were performed to evaluate the impact of clinical variables on DFS and OS. HER-2 protein expression, tumor size, tumor invasion, lymph node metastasis, Tumor-Node-Metastasis stage, perineural invasion (PNI) and lymphovascular invasion (LVI) were associated with inferior DFS. HER-2 protein expression emerged as an independent prognostic factor of DFS in HER-2-positive gastric cancer, but showed no association with OS. Compared with HER-2 immunhistochemistry (IHC) 2+ groups, patients with HER-2 IHC 3+ exhibited a higher prevalence of PNI and LVI, a shorter median DFS time, and a lower tumor-free survival rate at 1, 3 and 5 years post-surgery. In conclusion, HER-2 is a significant negative prognostic factor, associated with a poorer DFS time, although data on OS remain limited. HER-2 IHC 3+ gastric cancer is characterized by a higher prevalence of PNI and LVI.

gastric cancer clinicopathological features prognoses HER-2 protein disease-free survival

Funding: The present study was supported by the Startup Fund for Scientific Research, Fujian Medical University (grant no. 2022QH1276).

Introduction

Gastric cancer is a notable contributor to cancer-related morbidity and mortality worldwide, ranking fifth in terms of incidence and fourth in terms of mortality among all malignancies (1) Patients with gastric cancer in China represent over one-half of the worldwide total. Recent national data from 2022 reveal that gastric cancer has the third highest incidence and mortality rates among all cancer types in the country (2). Despite advancements in diagnosis and treatment, the overall survival (OS) rate remains low, with a 5-year survival rate <50%, dropping to <30% for advanced stages of the disease. Although trastuzumab has improved survival in human epidermal growth factor receptor-2 (HER-2)-positive disease and established anti-HER-2 therapy as a standard of care (3,4), overall outcomes remain poor. HER-2-positive tumors comprise 12-20% of gastric cancer cases (5) and represent a distinct therapeutic entity defined by the efficacy of anti-HER-2 agents. Although HER-2 upregulation portends inferior survival and heightened metastatic potential relative to HER-2-negative disease, existing evidence largely derives from dichotomous comparisons between these subgroups (6-9). Although research on the specific subtype of disease with low HER-2 expression in gastric cancer has increased (10,11), few studies have further differentiated this subgroup of HER-2-positive gastric cancer, leading to a limited understanding of whether variations in clinical characteristics and prognosis exist among patients with HER-2-positive gastric cancer with differing levels of HER-2 protein expression. Clinical data comparing immunohistochemistry (IHC) 2+ and 3+ HER-2-positive tumors, scored according to the Rüschoff/Hofmann grading system (12,13), remain limited. The present study stratified HER-2-positive gastric cancer by protein expression to evaluate its impact on clinicopathological features and survival.

Patients and methods <sec> <title>Patient enrollment and data collection

The present retrospective study examines clinical data from patients with HER-2-positive gastric cancer who underwent a radical gastrectomy at the Zhangzhou Affiliated Hospital of Fujian Medical University (Zhangzhou, China) between March 2017 and March 2023. All patients were of Asian ethnicity and originated from Zhangzhou, Fujian, China. Inclusion criteria necessitated patients to meet the following conditions: Preoperative clinical and imaging assessments indicating stage I-III gastric cancer according to the 8th edition of the American Joint Committee on Cancer Tumor-Node-Metastasis (TNM) system (14); successful radical resection (D2 lymphadenectomy and negative resection margins); postoperative pathological confirmation of gastric adenocarcinoma (International Classification of Diseases for Oncology no. C16 M8140/3); HER-2 status determined as IHC 3+ or 2+, with positive fluorescence in situ hybridization (FISH) in postoperative pathological specimens; and availability of comprehensive medical records. Exclusion criteria encompassed distant organ metastasis, concurrent malignancies, residual gastric cancer, incomplete medical documentation, or perioperative mortality attributed to surgical complications such as bleeding, septic shock or multiple organ failure. The study was approved by the Institutional Ethics Review Board of Zhangzhou Affiliated Hospital of Fujian Medical University (approval no. 2025LWB426).

Treatment strategy

All patients were treated according to clinical TNM staging. cT1-3N0-1M0 cases proceeded directly to radical gastrectomy, whereas cT3-4N1-3M0 cases received 2-4 cycles of neoadjuvant chemotherapy (fluoropyrimidine- or taxane-based plus platinum: FLOT, FOLFOX, XELOX/SOX or taxane-cisplatin) before surgery. Doses were as follows: Docetaxel, 50 mg/m²; oxaliplatin, 85-130 mg/m²; 5-FU, 2,400-2,600 mg/m²; capecitabine, 1,000 mg/m² BID; S-1, 40 mg/m² BID; cisplatin, 70-75 mg/m²; all on day 1, every 2-3 weeks. Adjuvant fluoropyrimidine-based chemotherapy was given to patients with pII (pT1-2N3M0) or pIII (pT3-4aN1-3M0) disease. Perioperative trastuzumab was not routinely used, in line with National Comprehensive Cancer Network, European Society for Medical Oncology, Chinese Society of Clinical Oncology and Japanese Gastric Cancer Association guidelines (15-18).

Detection of HER-2 expression

The expression of HER-2 protein in gastric cancer tissues was assessed using the Elivision two-step immunohistochemical method. The HER-2/neu rabbit monoclonal antibody (4B5; catalog number 790-2991; prediluted) from Roche Diagnostics (Shanghai) Co., Ltd., was applied on a Roche BenchmarkXT automated IHC platform. HER-2 IHC scoring was independently performed by two experienced gastrointestinal pathologists who were blinded to clinical outcomes. Discrepant or equivocal cases were resolved by consensus review using a multi-headed microscope. Immunostaining of HER-2 was categorized as 0, 1+, 2+ or 3+ utilizing the Rüschoff/Hofmann grading system (12,13). Tumor tissues with a score of 2+ underwent fluorescence in situ hybridization (FISH) analysis to confirm that they were indeed HER-2⁺. Scores of 0 were designated as HER-2-negative; 1+ and FISH-non-amplified 2+ cases were classified as low expression; and 3+ and FISH-amplified 2+ cases were considered HER-2-positive. FISH was performed on 4-µm FFPE sections using the Abbott PathVysion HER-2 DNA Probe Kit. Specimens were fixed in 10% neutral buffered formalin at room temperature for 24-48 h before processing and embedding. Deparaffinized sections were post-fixed in 10% neutral buffered formalin for 10 min at room temperature, then processed per the manufacturer's protocol (pretreatment at 80˚C for 30 min, protease digestion at 37˚C for 10 min, overnight hybridization at 37˚C with HER-2/neu and CEP17 probes). Tumor cells were identified on the corresponding H&E sections. At least 20 consecutive nuclei were scored, and the HER-2/CEP17 ratio was calculated. A HER-2/CEP17 ratio ≥2 indicated a HER-2-positive result, while a ratio <1.8 indicated a HER-2-negative result. Samples with ratios between 1.8 and 2 necessitated the evaluation of an additional 20-40 tumor cells, with a final ratio <1.8 classified as HER-2-negative and ≥2 as HER-2-positive. For cases between 1.8 and 2, a further 80-160 nuclei were counted, and the assessment was independently repeated by at least two observers to reach a consensus.

Statistical analysis

The associations between HER-2 protein expression and clinical characteristics were assessed through χ² testing. DFS and OS were analyzed using Kaplan-Meier curves with log-rank testing for between-group comparisons, and univariate and multivariate Cox regression analyses were performed to identify the associations between clinicopathological features and survival outcomes. All statistical analyses were conducted using SPSS 18.0 software (SPSS, Inc.), with P<0.05 used to indicate a statistically significant difference.

Results <sec> <title>Characteristics of the overall population

A total of 99 patients with HER-2-positive gastric cancer were included in the present study (Table I). The age of participants ranged from 32 to 86 years, with a median age of 68 years. The majority of individuals (58.6%) were aged ≥65 years, and the cohort was predominantly male (75.8%). The cohort primarily consisted of patients with intestinal-type gastric cancer (79.8%), well-differentiated tumors (57.6%), T3-4 infiltration depth (73.7%), stage III disease (59.6%), tumor size <5 cm (60.6%), lymph node metastasis (60.6%), LVI (76.8%), and PNI (75.8%). All patients exhibited proficient mismatch repair (pMMR), and 20 patients (20.2%) underwent neoadjuvant therapy. As of the last follow-up in February 2025, recurrence was observed in 47 patients (47.5%), and 33 patients (33.3%) passed away.

Univariate and multivariate analysis of the overall population

Univariate and multivariate analyses were conducted to determine the prognostic risk factors for HER-2-positive gastric cancer. The univariate Cox regression analysis showed that HER-2 expression (P=0.002), tumor size (P=0.003), depth of tumor invasion (P=0.002), presence of lymph node metastasis (P<0.001), TNM stage (P<0.001), PNI (P=0.001) and LVI (P=0.007) were associated with poor DFS. Furthermore, the multivariable Cox regression analysis revealed that HER-2 expression (P=0.039), lymph node metastasis (P=0.030) and PNI (P=0.040) were independent prognostic factors impacting DFS among patients with gastric cancer (Table II). Notably, the univariate Cox regression analysis showed that tumor size (P=0.014), tumor invasion (P=0.010), TNM stage (P=0.002), lymph node metastasis (P=0.009), and PNI (P=0.018) were associated with decreased OS. HER-2 expression (P=0.074) did not exhibit a significant association with OS in patients with gastric cancer. The multivariable Cox regression analysis revealed no independent prognostic factors for OS in these patients (Table III).

Different characteristics of gastric cancer with different HER-2 protein expression levels

HER-2 positivity was identified in 99 patients: 61 (61.6%) were IHC 3+ and 38 (38.4%) were IHC 2+ with FISH confirmation. These 38 FISH-positive cases represent 22.6% (38/168) of the initial IHC 2+ screening cohort (Fig. 1). Based on an analysis of clinicopathological characteristics according to HER-2 expression, it was found that PNI and LVI were more frequent in HER-2 IHC 3+ patients (51/61 and 51/61, respectively) than in IHC 2+ patients (24/38 and 25/38, respectively), with P=0.021 and P=0.041 for the respective comparisons. However, there were no statistically significant differences in terms of sex, age, TNM stage, Lauren classification, tumor size, tumor invasion or lymph node metastasis between the two groups (Table IV).

Survival outcome

The study involved 99 patients, with a median DFS time of 29 months [95% CI, 21-37) and a median OS time of 39 months (95% CI, 36-50). Kaplan-Meier survival analysis revealed a significantly shorter median DFS time in patients with HER-2 IHC 3+ compared with those in patients with HER-2 IHC 2+ (24 months vs. not reached, P=0.002). The disease-free survival rates at 1, 3 and 5 years post-operation were notably lower in patients with HER-2 IHC 3+ gastric cancer compared with those in patients with HER-2 IHC 2+ gastric cancer (81.96, 43.38 and 28.34% vs. 89.47, 76.02 and 72.02%; P=0.0009). However, the OS rates at 1, 3, and 5 years post-surgery exhibited no differences between patients with HER-2 IHC 3+ gastric cancer and those with HER-2 IHC 2+ gastric cancer (93.84, 63.47 and 52.01% vs. 94.74, 83.59 and 76.43%; P=0.0629) (Fig. 2).

Discussion

The HER-2 gene, located on the long arm of chromosome 17, encodes the ERBB-2 receptor protein situated on the cell membrane (19). This protein belongs to the epidermal growth factor receptor family and regulates various cellular functions, such as differentiation, apoptosis, adhesion, migration and growth, through the tyrosine kinase pathway upon activation (20). Overexpression or amplification of HER-2/ERBB-2 has been observed in breast cancer (21), colorectal cancer (22), lung cancer (23), tumors of the reproductive system (24), and gastric cancer (25).

Upregulation/amplification of HER-2 in breast cancer is associated with an unfavorable prognosis. Similarly, the HER-2 gene is an important prognostic factor for gastric cancer. Aznab et al (6) observed a marked difference in survival and mortality rates between patients with HER-2-positive and HER-2-negative gastric cancer. The analysis of HER-2 status and prognostic indicators in 97 patients with gastric cancer revealed a strong association between HER-2 status and the stage of the disease. Zhang et al (7) reported that patients with HER-2 upregulation had higher recurrence rates and shorter survival times. Moreover, HER-2 upregulation was identified as an independent prognostic factor following surgery for T3 gastric adenocarcinoma. Kurokawa et al (8) conducted a large-scale multicenter study to evaluate the prognostic implications of HER-2 expression in gastric cancer. The research demonstrated that patients with HER-2 positivity had markedly poorer survival outcomes compared with HER-2-negative individuals. Cheng et al (26) pooled 30 studies (n=9,945) and showed HER-2 upregulation was associated with worse OS in both resectable (HR, 1.56; 95% CI, 1.32-1.85) and advanced (HR, 1.70; 95% CI, 1.23-2.35) gastric cancer, supporting HER-2 positivity as an unfavorable prognostic biomarker. However, Kung et al (9) reported no marked differences in OS or DFS between patients with HER-2-negative and HER-2-positive gastric cancer after surgical resection (n=334), suggesting that HER-2 is not an independent prognostic factor. Notably, HER-2-positive tumors were associated with a higher risk of distant lymphatic recurrence. The present study identified HER-2 expression, tumor size, tumor invasion, lymph node metastasis, TNM stage, PNI and LVI as factors associated with reduced DFS in patients with HER-2-positive gastric cancer. Importantly, HER-2 expression, lymph node metastasis and PNI were identified as independent prognostic factors influencing DFS in patients with gastric cancer, which is consistent with the findings of Zhang et al (27). Additionally, the present study indicated that tumor size, tumor invasion, lymph node metastasis, PNI and LVI were associated with reduced OS time; however, no factors, including HER-2 protein expression, were independent prognostic factors in HER-2-positive gastric cancer. This result is in line with previous research by Fisher et al (28). Although individual studies report inconsistent prognostic implications of HER-2 in gastric cancer, most investigations and meta-analyses support HER-2 positivity as a marker of poor survival (7-9,26,27). Endogenous HER-2 upregulation drives an aggressive phenotype, largely through preferential formation of HER2/HER3 heterodimers that constitutively activate the PI3K/Akt and MAPK pathways, thereby promoting proliferation, angiogenesis, epithelial-mesenchymal transition and chemoresistance (29).

HER-2 status in clinical practice is primarily assessed by IHC and FISH. Although FISH is considered the gold standard owing to its high sensitivity, specificity and reproducibility, its widespread use is limited by technical complexity, specialized equipment requirements and high cost. IHC is a commonly used method to evaluate HER-2 protein expression due to its cost-effectiveness, rapid detection, and broad applicability in gastric and breast cancer (30,31). In the present study, the IHC method was employed for the initial screening of HER-2-positive gastric cancer. For cases with ambiguous IHC interpretation results, the FISH method was subsequently utilized for confirmation, which not only reduced testing costs but also enhanced the accuracy of the results. For the first time, HER-2-positive gastric cancer was stratified by protein expression level to evaluate its association with clinicopathological features and survival. These findings provide evidence to guide prognostic assessment and targeted therapy in this patient population.

In the present study, HER-2 protein expression was not significantly associated with sex, age, tumor differentiation, TNM stage, Lauren classification, tumor size, depth of invasion or lymph node status. However, HER-2-positive tumors, particularly IHC 3+ cases, were more frequently characterized by perineural and lymphovascular invasion. Although the current TNM classification does not include LVI and PNI, these factors are widely recognized by researchers as being linked to the aggressive biological behavior of tumors (32-34). LVI refers to the invasion, destruction or presence of tumor cells within the lumen of small blood vessels and lymphatic vessels in and around the tumor area under microscopic examination (35). A previous study found that LVI is a prognostic factor for gastric cancer. Positive LVI in patients with gastric cancer was linked to malignancy, deeper invasion, lymph node metastasis and a worse prognosis (36). Wu et al (37) showed that LVI correlates with deeper invasion, greater nodal burden and lower overall survival rate. PNI, an independent dissemination pathway, is a well-established predictor of early recurrence and poor prognosis in gastric cancer. Patients with gastric cancer positive for PNI have higher rates of postoperative local recurrence and lower OS rates (38). Sun et al (39) reported that, in patients with locally advanced gastric cancer receiving neoadjuvant therapy followed by surgery, PNI and lymph node metastasis were independent prognostic factors. These findings underscore that both LVI and PNI are key determinants of survival in gastric cancer. Patients with both perineural and lymphovascular invasion in gastric cancer face an increased risk of lymph node metastasis and a poorer prognosis (34). Studies show that nerves, together with blood vessels and lymphatic vessels, collectively constitute the external microenvironment for tumor growth; their interaction with tumor cells promotes tumorigenesis and progression (40,41). A study also showed that VEGF expression is upregulated in gastric cancer tissues. By promoting angiogenesis and generating structurally immature vessels with defective basement membranes, VEGF facilitates tumor cell intravasation and hematogenous dissemination (42). PNI is currently considered a special mode of tumor metastasis; it involves complex interactions between tumor cells, stromal cells, surrounding immune cells and nerve fibers (40,43). Current understanding of the biological mechanisms underlying LET/PNI in gastric cancer is limited, and the interaction with the HER-2 gene is even more poorly understood. This gap highlights the imperative for future, in-depth research to elucidate these clinically important mechanisms.

Patients with HER-2 IHC 3+ gastric cancer may exhibit unfavorable biological characteristics associated with increased recurrence and risk of metastasis. The present study found that HER-2 IHC 3+ patients had significantly shorter median DFS times compared with HER-2 2+ patients. Additionally, the DFS rates at 1, 3 and 5 years post-surgery were notably lower for patients with HER-2 3+ gastric cancer compared with patients with HER-2 2+ gastric cancer, indicating a heightened vulnerability to postoperative recurrence and metastasis. Although 1-, 3- and 5-year OS rates did not differ significantly between patients with HER-2 IHC 3+ and 2+ gastric cancer, survival trends suggested a potential disadvantage for HER-2 IHC 3+ cases, a pattern that may become more pronounced with extended follow-up.

In conclusion, patients with HER-2 IHC 3+ gastric cancer demonstrate elevated rates of post-surgical recurrence and metastasis, resulting in a reduced OS time. It is advisable to maintain vigilant monitoring and implement intensified postoperative surveillance protocols for this patient group to detect signs of tumor recurrence and metastasis promptly. Furthermore, the potential efficacy of anti-HER-2 therapy in enhancing survival outcomes among these individuals warrants additional investigation.

Limitations include the single-center, retrospective design and selection of only surgically resectable cases, limiting generalizability. Potential bias from HER-2 heterogeneity across Lauren subtypes and the absence of dynamic HER-2 monitoring may further affect interpretation. Larger, multi-center prospective studies with serial HER-2 assessments are needed.

In conclusion, HER-2 is a significant negative prognostic factor associated with poorer DFS, although data on OS remain limited. HER-2 IHC 3+ gastric cancer exhibits a higher prevalence of PNI and LVI, as well as an elevated risk of postoperative recurrence and metastasis.

Acknowledgements

Not applicable.

Availability of data and materials

The data generated in the present study may be requested from the corresponding author.

Authors' contributions

HS contributed substantially to study conception, design, data acquisition, analysis, and interpretation, and wrote the main manuscript. SL conceived the research idea and critically revised the manuscript. HS and HH confirm the authenticity of all the raw data. XX contributed to data acquisition through active participation in both data analysis and interpretation, and co-wrote the first draft. HH prepared the figures and tables, involving data selection and organization for visual presentation, and contributed to manuscript revision. HH was also actively engaged in the interpretation of pathological data, playing a crucial role in elucidating the pathological findings and their correlation with the clinical data. All authors commented on previous versions of the manuscript. All authors read and approved the final version of the manuscript.

Ethics approval and consent to participate

All procedures involving human participants were performed according to the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Institutional Research Ethics Committee of Zhangzhou Hospital Affiliated with Fujian Medical University (approval no. 2025LWB426). As a retrospective study, the requirement for informed consent was waived by the ethics committee.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References 1

Sung

Ferlay

Siegel

Laversanne

Soerjomataram

Jemal

Bray

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

CA Cancer J Clin712092492021

33538338

10.3322/caac.21660

Xia

Dong

Cao

Sun

Yang

Yan

Zhang

Chen

Cancer statistics in China and United States, 2022: Profiles, trends, and determinants

Chin Med J (Engl)1355845902022

35143424

10.1097/CM9.0000000000002108

Bang

Van Cutsem

Feyereislova

Chung

Shen

Sawaki

Lordick

Ohtsu

Omuro

Satoh

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial

Lancet3766876972010

20728210

10.1016/S0140-6736(10)61121-X

Boku

HER2-positive gastric cancer

Gastric Cancer171122014

23563986

10.1007/s10120-013-0252-z

Meric-Bernstam

Johnson

Dumbrava

Raghav

Balaji

Bhatt

Murthy

Rodon

Piha-Paul

Advances in HER2-targeted therapy: Novel agents and opportunities beyond breast and gastric cancer

Clin Cancer Res25203320412019

30442682

10.1158/1078-0432.CCR-18-2275

Aznab

Maleksabet

Khazaei

Rezaei

The role of human epidermal growth factor receptor (HER2/neu) in the prognosis of patients with gastric cancer

Asian Pac J Cancer Prev20198919942019

31350955

10.31557/APJCP.2019.20.7.1989

Zhang

Wang

Huang

Wang

Song

Lin

Wang

Jiang

Huang

Wang

Overexpression of HER-2 protein is a high-risk factor for patients with surgically-resected stage T3 gastric adenocarcinoma

Clin Lab631151252017

28164509

10.7754/Clin.Lab.2016.160704

Kurokawa

Matsuura

Kimura

Adachi

Fujita

Imamura

Kobayashi

Yokoyama

Shaker

Takiguchi

Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer

Gastric Cancer186916972015

25224659

10.1007/s10120-014-0430-7

Kung

Huang

Lin

Hung

Chen

Chao

AFY

Fang

Lan

Clinicopathologic features and prognosis of HER2-positive gastric cancer

Int Surg10868772024

Narita

Mizuno

Ishizuka

Sakakida

Masuishi

Taniguchi

Kadowaki

Honda

Ando

Tajika

Clinicopathological and prognostic significance of HER2-low expression in advanced gastric cancer: A retrospective observational study

Oncologist30oyae3282025

39673418

10.1093/oncolo/oyae328

Gokon

Nakashima

Ohki

Ogino

Hatoyama

Shimizu

Kashiwadate

Katsura

Abe

Sato

Prognostic significance of low HER2 expression in gastric cancer: A retrospective, single-center analysis

BMC Cancer2410812024

39223480

10.1186/s12885-024-12749-x

Hofmann

Stoss

Shi

Büttner

van de Vijver

Kim

Ochiai

Rüschoff

Henkel

Assessment of a HER2 scoring system for gastric cancer: Results from a validation study

Histopathology527978052008

18422971

10.1111/j.1365-2559.2008.03028.x

Rüschoff

Dietel

Baretton

Arbogast

Walch

Monges

Chenard

Penault-Llorca

Nagelmeier

Schlake

HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing

Virchows Arch4572993072010

20665045

10.1007/s00428-010-0952-2

Amin

Edge

Greene

Byrd

Brookland

Washington

Gershenwald

Compton

Hess

Sullivan

AJCC cancer staging manual. 8th ed. New York: Springer; 2017. 1032 p. ISBN 978-3-319-40617-6.

Ajani

D'Amico

Almhanna

Bentrem

Chao

Das

Denlinger

Fanta

Farjah

Fuchs

Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology

J Natl Compr Canc Netw14128613122017

Smyth

Verheij

Allum

Cunningham

Cervantes

Arnold

ESMO Guidelines Committee

Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Ann Oncol27(suppl 5)v38v492016

27664260

10.1093/annonc/mdw350

Chinese Society of Clinical Oncology (CSCO) Guidelines Working Committee. Guidelines of Chinese Society of Clinical Oncology (CSCO): Primary Gastric Cancer. 2017.V1. Beijing: People's Medical Publishing House; 2017. ISBN 978-7-117-24380-3. https://www.pmphmall.com/gdsdetail/609686-284313.

Japanese Gastric Cancer Association

Japanese gastric cancer treatment guidelines 2014 (ver. 4)

Gastric Cancer201192017

27342689

10.1007/s10120-016-0622-4

Wang

Amemiya

Henry

Seth

Hanna

Hsieh

Multiplex ligation-dependent probe amplification can clarify HER2 status in gastric cancers with ‘Polysomy 17’

J Cancer64034082015

25874002

10.7150/jca.11424

Sekaran

Kandagaddala

Darisetty

Lakhtakia

Ayyagari

Rao

Rebala

Reddy

HER2 expression in gastric cancer in Indian population-an immunohistochemistry and fluorescence in situ hybridization study

Indian J Gastroenterol311061102012

22760626

10.1007/s12664-012-0214-0

Dempsey

Sandoval

Mahtani

Metastatic HER2-positive breast cancer: Is there an optimal sequence of therapy?

Curr Treat Options Oncol24112011372023

37428332

10.1007/s11864-023-01108-w

Benli

Arikan

Akbulut-Caliskan

HER2-targeted therapy in colorectal cancer: A comprehensive review

Clin Transl Oncol27360736242025

40087250

10.1007/s12094-025-03887-0

Odintsov

Makarem

Nishino

Bachert

Zhang

LoPiccolo

Paweletz

Gokhale

Ivanova

Saldanha

Prevalence and therapeutic targeting of high-level ERBB2 amplification in NSCLC

J Thorac Oncol197327482024

38154514

10.1016/j.jtho.2023.12.019

Edjtemaei

Nili

Jahanzad

Ameli

Ghasemi

HER-2 overexpression in female genital tract clear cell carcinomas: Evaluation of different scoring guidelines, clinicopathological features and prognostic impact

Ann Diagn Pathol661521842023

37543027

10.1016/j.anndiagpath.2023.152184

Matsusaka

Nashimoto

Nishikawa

Miki

Miwa

Yamaguchi

Yoshikawa

Ochiai

Morita

Sano

Clinicopathological factors associated with HER2 status in gastric cancer: Results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101)

Gastric Cancer198398512016

26265390

10.1007/s10120-015-0518-8

Cheng

Cai

Wang

Tao

HER2 becomes a novel survival biomarker for gastric cancer patients: A pooled analysis

Ther Adv Med Oncol16127166492024

39281969

10.1177/17588359241271913

Zhang

Shen

Chen

Wang

Zheng

The expression and prognostic predictive value of PD-L2 in patients undergoing radical gastric cancer surgery

Future Sci OA1125269932025

40599033

10.1080/20565623.2025.2526993

Fisher

Squires

MR III

Patel

Kooby

El-Rayes

Cardona

Russell

Staley

CA III

Farris

AB III

Maithel

HER2 in resected gastric cancer: Is there prognostic value?

J Surg Oncol10961662014

24122802

10.1002/jso.23456

Gravalos

Jimeno

HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target

Ann Oncol19152315292008

18441328

10.1093/annonc/mdn169

Sakaguchi

Maebayashi

Aizawa

Ishibashi

Whole-brain radiation therapy for breast cancer patients with dural metastasis without concomitant brain metastasis and leptomeningeal metastasis

Anticancer Res38640564112018

30396965

10.21873/anticanres.13001

The Society of Breast Cancer China Anti-Cancer Association; Breast Oncology Group of the Oncology Branch of the Chinese Medical Association

Guidelines and Specifications for the Diagnosis and Treatment of Breast Cancer in China (2024 Edition)

Chinese J Cancer33109211872023

Kang

Son

Kim

Park

Kim

Recurrence-free survival outcomes based on novel classification combining lymphovascular invasion, perineural invasion, and T4 status in stage II-III colon cancer

Cancer Manag Res14203120402022

35757161

10.2147/CMAR.S358939

Sun

Liu

Luo

Zhang

Zhu

Zhang

Perineural and lymphovascular invasion predicts for poor prognosis in locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery

J Cancer10224322492019

31258728

10.7150/jca.31473

Zhang

Chen

Luo

Xiong

Yin

Jin

Chen

Peng

Lian

Lymphovascular or perineural invasion is associated with lymph node metastasis and survival outcomes in patients with gastric cancer

Cancer Med12940194082023

36952439

10.1002/cam4.5701

Zhu

Ling

Zhang

Luo

Yun

Xie

Cai

The prognostic significance of lymphovascular invasion in patients with resectable gastric cancer: A large retrospective study from Southern China

BMC Cancer153702015

25947284

10.1186/s12885-015-1370-2

Fujikawa

Koumori

Watanabe

Kano

Shimoda

Aoyama

Yamada

Hiroshi

Yamamoto

Cho

The clinical significance of lymphovascular invasion in gastric cancer

In Vivo34153315392020

32354959

10.21873/invivo.11942

Liang

Zhang

Wang

Ding

Huang

Liang

Prognostic significance of lymphovascular infiltration in overall survival of gastric cancer patients after surgery with curative intent

Chin J Cancer Res317857962019

31814682

10.21147/j.issn.1000-9604.2019.05.08

Zhao

Mei

Luo

Bao

Huang

Lin

Perineural invasion as a predictive factor for survival outcome in gastric cancer patients: A systematic review and meta-analysis

J Clin Pathol735445512020

31980559

10.1136/jclinpath-2019-206372

Sun

Yang

Wang

Zhao

Cai

Zhang

Huang

Zhou

Prognostic factors associated with locally advanced gastric cancer patients treated with neoadjuvant chemotherapy followed by surgical resection

Oncotarget875186751942017

29088856

10.18632/oncotarget.20660

Zhou

Chen

Yin

Yao

Zhang

Preliminary study correlating CX3CL1/CX3CR1 expression with gastric carcinoma and gastric carcinoma perineural invasion

World J Gastroenterol20442844322014

24764683

10.3748/wjg.v20.i15.4428

Gao

Zhou

Zhang

Xiang

Wang

Zhang

Lymphangiogenesis in gastric carcinoma correlates with prognosis

J Pathol2181922002009

19224540

10.1002/path.2523

Tao

Qin

Lin

Wang

Expression of vascular endothelial growth factor and its prognostic significance in gastric carcinoma

World J Gastroenterol21281301996

Amit

Na'ara

Gil

Mechanisms of cancer dissemination along nerves

Nat Rev Cancer163994082016

27150016

10.1038/nrc.2016.38

Figure 1

Immunohistochemical staining and fluorescence in situ hybridization of HER-2. (A) HER-2 2+ (x200 magnification); (B) HER-2 3+ (x200 magnification); (C) positive HER-2 gene amplification (x1,000 magnification). Arrows indicate HER2 (red) and CEP17 (green) signals. HER-2, human epidermal growth factor receptor-2; CEP17, chromosome enumeration probe 17.

Figure 2

DFS and OS of patients in the HER-2 IHC 2+ and HER-2 IHC 3+ groups. (A) DFS and (B) OS. DFS, disease-free survival; OS, overall survival.

Table I

Clinical characteristics of patients with gastric cancer.

Characteristics	n (%)
Total	99 (100.0)
Sex
Male	75 (75.8)
Female	24 (24.2)
Age, years
<65	41 (41.4)
≥65	58 (58.6)
Differentiation
Poor	42 (42.4)
Well	57 (57.6)
Lymphovascular invasion
No	23 (23.2)
Yes	76 (76.8)
TNM stage
I-II	40 (40.4)
III	59 (59.6)
Tumor invasion
T1-2	26 (26.3)
T3-4	73 (73.7)
HER-2 expression
IHC 2+	38 (38.4)
IHC 3+	61 (61.6)
Lauren type
Intestinal	79 (79.8)
Non-intestinal	20 (20.2)
Tumor size, cm
<5	60 (60.6)
≥5	39 (39.4)
Perineural invasion
No	24 (24.2)
Yes	75 (75.8)
Lymph node metastasis
Negative	39 (39.4)
Positive	60 (60.6)
Neoadjuvant therapy
No	79 (79.8)
Yes	20 (20.2)
Follow-up outcome
Recurrence	47 (47.5)
Death	33 (33.3)

TNM stage, Tumor-Node-Metastasis stage; IHC, immunohistochemistry; HER-2, human epidermal growth factor receptor-2.

Table II

Univariate and multivariate Cox regression analysis of disease-free survival.

	Univariate analysis			Multivariate analysis
Variables	HR (95% CI)		P-value	HR (95% CI)		P-value
Sex (male/female)	1.081	0.516-2.006	0.960
Age (<65/≥65 years)	1.030	0.577-1.838	0.921
Differentiation (well/poor)	0.778	0.437-1.384	0.393
TNM stage (I-II/III)	4.392	2.048-9.421	<0.001	0.759	0.219-2.629	0.664
Lauren type (intestinal/non-intestinal)	1.281	0.637-2.578	0.487
Tumor size (<5/≥5 cm)	2.372	1.332-4.228	0.003	1.718	0.934-3.159	0.082
Tumor invasion (T1-2/T3-4)	5.277	1.889-14.74	0.002	1.510	0.416-5.477	0.531
Lymph node metastasis (no/yes)	4.842	2.166-10.82	<0.001	3.796	1.140-12.63	0.030
Perineural invasion (no/yes)	9.978	2.417-41.18	0.001	7.592	1.101-52.36	0.040
Lymphovascular invasion (no/yes)	4.113	1.474-11.47	0.007	0.337	0.081-1.397	0.134
HER-2 expression (IHC 2+/IHC 3+)	3.045	1.504-6.167	0.002	2.167	1.038-4.520	0.039

TNM, Tumor-Node-Metastasis; IHC, immunohistochemistry; HR, hazard ratio; CI, confidence interval; HER-2, human epidermal growth factor receptor-2.

Table III

Univariate and multivariate analysis of overall survival.

	Univariate analysis			Multivariate analysis
Variables	HR (95% CI)		P-value	HR (95% CI)		P-value
Sex (male/female)	0.948	0.623-1.441	0.801
Age (<65/≥65 years)	0.829	0.581-1.184	0.303
Differentiation (well/poor)	1.645	0.911-1.180	0.154
TNM stage (I-II/III)	4.354	1.680-11.28	0.002	1.699	0.329-8.767	0.526
Lauren type (intestinal/non-intestinal)	1.827	0.848-3.937	0.124
Tumor size (<5/≥5 cm)	2.364	1.188-4.703	0.014	1.657	0.810-3.390	0.167
Tumor invasion (T1-2/T3-4)	6.611	1.581-27.64	0.010	2.443	0.393-15.19	0.338
Lymph node metastasis (no/yes)	3.239	1.337-7.849	0.009	1.340	0.337-5.332	0.678
Perineural invasion (no/yes)	5.630	1.347-23.53	0.018	1.525	0.241-9.646	0.654
Lymphovascular invasion (no/yes)	2.422	0.850-6.896	0.098
HER-2expression (IHC 2+/IHC 3+)	2.015	0.934-4.349	0.074

TNM, Tumor-Node-Metastasis; IHC, immunohistochemistry; HR, hazard ratio; CI, confidence interval; HER-2, human epidermal growth factor receptor-2.

Table IV

Characteristics of gastric cancer with different HER-2 protein expression.

Characteristics	HER-2 IHC 2+	HER-2 IHC 3+	P-value
Sex, n (%)			0.919
Male	29	46
Female	9	15
Age, n (%)			0.912
<65 years	16	25
≥65 years	22	36
Differentiation, n (%)			0.713
Poor	17	25
Well	21	36
TNM stage, n (%)
I-II	19	21	0.125
III	19	40
Lauren type, n (%)			0.232
Intestinal	28	51
Non-intestinal	10	10
Tumor size, n (%)			0.093
<5 cm	27	33
≥5 cm	11	28
Tumor invasion, n (%)			0.059
T1-2	14	10
T3-4	24	51
Lymph node metastasis, n (%)			0.088
No	19	20
Yes	19	41
Perineural invasion, n (%)			0.021
No	14	10
Yes	24	51
Lymphovascular invasion, n (%)			0.041
No	13	10
Yes	25	51
Neoadjuvant therapy, n (%)
No	33	46	0.168
Yes	5	15

TNM, Tumor-Node-Metastasis; HER-2, human epidermal growth factor receptor-2; IHC, immunohistochemistry.